Drug rash with eosinophilia and systemic symptoms related to brentuximab vedotin: A report of 2 cases

Drug rash with eosinophilia and systemic symptoms related to brentuximab vedotin: A report of 2 cases

Bibliographic Details
Main Authors:	Laura Ragmanauskaite, MD, Meera Brahmbhatt, MD, Justin T. Cheeley, MD
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	JAAD Case Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512620306159

Similar Items

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

Polycyclic rash with persistent eosinophilia
by: Lauren E. Merz, MD, MSc, et al.
Published: (2021-06-01)

Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: a case report
by: Attilio Di Girolamo, et al.
Published: (2018-10-01)

Ceftriaxone induced drug rash with eosinophilia and systemic symptoms
by: Vivek S Guleria, et al.
Published: (2014-01-01)

Diagnostic criteria for drug rash and eosinophilia with systemic symptoms
by: Ashok Kumar Pannu, et al.
Published: (2017-01-01)

Real experience of brentuximab vedotin for cutaneous T cell lymphomas
by: F. Keklik Karadag, et al.
Published: (2020-10-01)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
by: Lai C, et al.
Published: (2019-12-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
by: Hung-Bo Wu, et al.
Published: (2013-01-01)

Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib
by: Camille Pinard, MD, et al.
Published: (2017-11-01)

Brentuximab vedotin therapy for cutaneous lesions in T-prolymphocytic leukemia: a case report
by: Jordan Senchak, et al.
Published: (2016-09-01)

Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome
by: Peter A. Young, MPAS, BS, et al.
Published: (2021-03-01)

Drug rash with eosinophilia and systemic symptoms syndrome due to quinine
by: Bankar R, et al.
Published: (2007-01-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
by: Makita S, et al.
Published: (2020-06-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

Drug Rash with Eosinophilia and Systemic Symptoms: Two Emergency Department Cases
by: Adam Landman, et al.
Published: (2011-05-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)

Sulfasalazine-induced DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms)
by: Renata Telles Rudge de Aquino, et al.

Drug reaction/rash with eosinophilia and systemic symptoms syndrome caused by antibacillary drugs: a case report
by: Sofia Baina, et al.
Published: (2021-01-01)

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
by: Chen R, et al.
Published: (2016-04-01)

Letter to the editor "Drug rash with eosinophilia and systemic symptoms syndrome induced by carbamazepine: Case report"
by: Andrés Puerto-Fuentes, et al.
Published: (2017-09-01)

The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL
by: Rebecca L. Allchin, et al.
Published: (2020-12-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
by: Michelle Furtado, et al.
Published: (2012-01-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin
by: Michelle Furtado, et al.
Published: (2012-01-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

Brentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Review
by: Berger, Garrett, et al.
Published: (2017)

Pneumocystis jirovecii Pneumonia during Brentuximab Vedotin Therapy: A Case Report and Literature Review
by: Aliana Meneses Ferreira, et al.
Published: (2019-01-01)

Intravenous immunoglobulin in the treatment of drug rash eosinophilia and systemic symptoms caused by phenytoin
by: Ponnusamy Santhamoorthy, et al.
Published: (2012-01-01)

Drug rash with eosinophilia and systemic symptoms syndrome due to anti-TB medication
by: Dharmesh H Kaswala
Published: (2013-01-01)

Anti-tuberculosis treatment-induced Drug Rash with Eosinophilia and Systemic Symptoms syndrome
by: Sandip Bartakke, et al.
Published: (2016-01-01)

DRESS syndrome (drug rash with eosinophilia and systemic symptoms): sometimes, not all signs are there
by: Fábio Murteira, et al.
Published: (2021-09-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
by: Joana Ferra, et al.
Published: (2021-02-01)

Testing sensitivity to cd30 targeting via brentuximab vedotin in multiple myeloma
by: E. La Spina, et al.
Published: (2020-09-01)

CD30 - the head of TNF-family… or a successful story of brentuximab vedotin
by: Popović Lazar, et al.
Published: (2013-01-01)

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
by: Illidge T, et al.
Published: (2012-05-01)

Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
by: Laura Esser, et al.
Published: (2016-07-01)